Journal article
Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients
Abstract
Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time. It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods. This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer. Consecutive consenting patients from one center in a multicenter trial that …
Authors
Kovacs MJ; Levine MN; Keeney M; Mackinnon KM; Lee AY
Journal
Thrombosis and Haemostasis, Vol. 93, No. 06, pp. 1185–1188
Publisher
Thieme
Publication Date
2005
DOI
10.1160/th05-01-0052
ISSN
0340-6245